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Abstract: Thirty-eight sequentially placed liver and kidney allografts were evaluated with respect 10 
patient and graft survival. and the influence of preformed Iymphocytotoxic antibodies was analysed. The 
results suggest that the survival rate of combined liver and kidney transplantation is similar to the 
survival rate of liver transplantation alone. Sequentially placed kidney allografts may be protected from 
hyperacute rejection m the presence of donor specific Iymphocytotoxic antibodies. but not in all 
instances. Both pallent and kidnev allograft survIval was lower in positive crossmatch patients (33°1., and 
17% respectivelv) Ihan in negallve crossmatch patients (78% and 75%). High levels of panel reactive 
antibodies (>10%) also appeared to have a deleteriOUs effect on survival. although the majority of the 
pattents who failed also had a positive crossmatch. Although preformed Iymphocytotoxlc anllbodies arc 
110t an absolute contramdication to combined IiVt:r-kldnev transplantation. they do appear to have a 
deleteriOus effect on long-term graft survival. However. more correlation with clinical parameters IS 
needed. 
Introduction 
It is hecoming common for patients suffering from hoth 
hepatic and renal dysfunction to be referred for organ 
transplantation. Concomitant renal and hepatic failure mav 
result from the same disease process (e.g. polycystic disease i, 
Ilr one coexisting disease may he a result of the other (e.g. 
post viral hepatitic cirrhosis in a dialysis patient ).1 Patients 
with liver failure may also have an intrinsic renal defect (e.g. 
interstitial nephritis I or renal dysfunction resulting from Iiv;r 
failure (e.g. hepatorenal svndrome or nephrotoxicitv of cvelo-
'porine 111 patients reqUiring liver retransplantation). In any 
.:ase. management of a liver transplant recipient IS greatlv 
.:omplicated hy the presence of renal dysfunction.; In those 
patients who have demonstrated irreversible and severe renal 
impairment. combined liver-kidney transplantation must he 
conSidered. 
.·\ddress tor correspondence: Susan L Saidman. Histocompatlbllitv 
L.lboralOry. Massachusells General Hospital. 32 Fruit Street. Boston. 
\IA m114. USA. 
I' Edward Arnold 1994 
The effect of various immunological parameters on patient 
and graft survival in liver as well as in kidney transplantation 
has been reported. In renal transplantation. the degree of 
presensitization and the donor specific crossmatch can he 
clearly correlated with graft survival. More recently, a sli~ht 
disadvantage has also heen noted when liver grafts are placed 
into a presensitized recipient.JA although the effect is much 
less dramatic. Reports of successful combined liver-kidney 
transplants have heen published.'-II hut the effect of pre-
formed Iymphocytotoxic antibodies on such transplants IS 
unclear. 
Objective 
In this study we report our experience with 38 patients who 
received simultaneous liver-kidney transplants at the Uni-
versity of Pittsburgh. The patient and gralt survival of these 
patients was correlated with immunological parameters. in-
cluding donor specific crossmatch and the level of panel 
TOle 1 Clinical profile of liver-kidney recipients 
Patie;1t Age Sex Previous 
number (years) transplants 
1 19 F Liver 
2 42 F No 
3 15 F No 
4 43 F No 
5 36 M No 
6 6S M No 
7 12 M No 
8 15 M Liver 
9 61 M No 
10 48 M No 
11 63 M Liver x2 
12 47 M No 
13 48 M Kidney 
14 54 M No 
15 43 M No 
16 43 F No 
17 64 F No 
18 5 M No 
19 31 M No 
20 48 M No 
21 44 M Kidney 
22 29 M Kidney x2 
23 50 M No 
24 .w M Kidney x2 
25 50 F No 
26 19 M Kidney 
27 14 M Kidney 
28 20 M Liver x2 
29 56 M No 
30 23 F Liver 
31 61 F No 
32 25 F Liver x2 
33 62 F No 
34 69 M No 
35 63 F No 
36 8 F No 
37 58 M No 
3X 44 M Kidney 
NO, not determined. 
reactive antibodies (PRA) prior to transplant, in an attempt 
to determine the effect of preformed Iymphocytotoxic anti-
hodies on combined liver-kidney transplantation. 
Materials and methods 
During the seven year period from August 1983 to August 
1992. 38 patients received combined liver-kidney transplants 
from single donors. Table I lists the clinical demographics for 
these patients. Twenty-five of the patients were male. while 
13 were female. The age range was from five years to 69 years. 
with a median age of 44 years. Previous organ transplantation 
consisted of nine liver allografts into six recipients, and eight 
kidney allografts into six recipients. The timing of the prior 
transplants varied considerably between patients. 
The causes of organ failure were varied. Seven patients had 
combined polycystic liver and kidney disease. and three had 
oxalosis which resulted in both liver and kidney failure. Seven 
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ll1De of previous Current Donor 
transplant 'l'oPRA crossmatch 
(months prior) 
71 NO Negative 
NO Negative 
NO Negative 
94 Positive 
0 Negative 
20 Positive 
91 Positive 
35 5 Negative 
20 Negative 
0 Negative 
0.6.0.5 64 Positive 
2 Negative 
-60 26 Negative 
0 Negative 
29 Negative 
14 Negative 
3 Negative 
1 Negative 
0 Negative 
0 Negative 
85 10 Negative 
-144. -132 98 Positive 
6 Negative 
49,23 0 Negative 
0 Negative 
-84 0 Negative 
-72 2 Negative 
12,11 76 Positive 
0 Negative 
5 0 Negative 
() Negative 
17,15 6 Negative 
() Negative 
() Negative 
13 Negative 
() Negative 
() Negative 
Xl 1X Negative 
patients had liver failure due to non-A non B-hepatitis, two 
had hepatitis B and five had hepatitis C. Three patients had 
Laennec's cirrhosis. II others had a variety of cholestatic 
cirrhosis or hepatocellular disease. The causes of kidney 
failure were as varied as the aetiologies of liver failure. The 
leading causes were polycystic kidney disease (n = 7) and 
diabetic nephropathy (II = n). Other less common causes 
included oxalosis and cyclosporine nephrotoxicity among 
others. 
The liver and kidney transplants were performed as pre-
viously deseribedK~ Between August 1983 and August 1989. 18 
liver-kidney combinations received a baseline immunosup-
pression regimen consisting of cyclosporine. steroids and 
azathioprine. After this period. the remaining patients re-
ceived the investigational immunosuppressive agent FK506. 
in combination with low-dose steroids. 
The percentage of panel reactive antibodies (PRA) was 
determined using the standard modified Amos technique at 
room temperature. against a panel of at least 50 HLA se-
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lected lymphocytes. In all but three cases. pretransplant sera 
were obtained within two days prior to surgery. Three 
patients (patients 5. 10 and 28) had their most recent serum 
drawn 18. 8 and 13 days prior to surgery, respectively. 
Historical sera were also analysed when available. All donorl 
recipient combinations were ABO identical, but HLA type 
played no role in donor selection. 
Peripheral blood lymphocytes. lymph node cells and spleen 
cells were typed for HLA-A and -B antigens by either the 
Amos modified or standard NIH microlymphocytotoxicity 
technique with trypan blue dye exclusion. Serological typing 
for HLA-DR was done using either two colour fluorochro-
masia or microlymphocytotoxicity with B lymphocytes iso-
lated from antibody coated magnetic beads. The donor 
lymphocytotoxic crossmatches were done using the standard 
modified Amos technique at room temperature against either 
unfractionated lymphocytes or T cells isolated from donor 
lymph nodes. The crossmatch was considered to be positive 
when more than 20% of the lymphocytes were killed. 
Actuarial survivals were calculated using the Kaplan-
Meier (product-limit) method. Differences between groups 
were compared using the log rank test. Statistical analysis was 
performed using the SPSS for MS Windows program. 
Results 
Overall patient and graft survival 
Of the 38 patients undergoing combined liver-kidney trans-
plantation. 26 (68%) are alive with follow-up times from 11 
months to nine years. which is comparable to the overall 
survival of patients receiving liver transplants alone during 
this time period. 12 Figure I shows the actuarial patient 
survivals for the 38 cases. As is true for those patients 
receiving liver allografts alone. the majority of deaths andlor 
graft failures occurred during the first three months. Twenty-
six of the 38 transplanted livers (68%) are still functioning. 
Six patients died with their combined transplants in place. Of 
the six patients who underwent retransplantation of the liver. 
live died within six weeks and one died 14 months later. Two 
kidney allografts have been lost (patients 7 and 14) without 
accompanying patient death. kaving an overall kidney graft 
survival of 60%, 
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Influence of c:rossmatch on patient and graft 
survival 
Lymphocytotoxic crossmatches were negative in 32 patients 
at the time of transplantation and 25/32 (78%) are alive. all 
but one with functioning kidneys. Four of the six patients with 
a positive crossmatch have died (33% survival) and a fifth 
rejected his kidney. Actuarial patient and renal graft survival 
for these two groups of patients are shown in Figure 2. There 
is a statistically significant difference in both the patient 
survival (p = 0.04) and kidney allograft survival (p = 0.001) 
between the two groups. 
Table 2 summarizes the clinical course of the six patients 
with a positive crossmatch. Patient 4 was previously reported 
as a case in which the liver transplant protected the kidney 
from hyperacute rejection.6 She had a relatively benign 
postoperative course and continues to do well over eight 
years post-transplant. Patient 6 was also reported in the same 
paper.6 He did well until nine days posttransplant, when he 
underwent rejection of both allografts. but both organs 
responded to OKTI treatment. However, three months post-
transplant he was diagnosed with Pneumocystis carinii infec-
tion and died two weeks later. Neither allograft showed signs 
of immunological damage at the time of his death. 
Patient 7 has been described by StaTZI et al. 13 as a case in 
which the immediate nonfunction of the transplanted kidney 
warned of developing liver damage. The liver showed signs of 
severe dysfunction for two weeks posttransplant. but re-
covered and continues to function well. The transplanted 
kidney never functioned. but a subsequent crossmatch neg· 
ative kidney transplant was successful 11 months later, 
Patient 11 received a liver-kidney transplant after the 
failure of two livers transplanted within the prior three weeks. 
The patient suffered from graft-versus-host disease after the 
second liver (due to ABO nonidentity) and still had severe 
haemolysis at the time of the combined liver-kidney trans-
plant. He died of multisystem failure and sepsis. with no 
evidence of immunological damage to the liver or kidney. It is 
not clear whether a residual effect of OKT3 last administered 
four days prior to the combined transplant resulted in a 
falsely positive crossmatch." 
[n patient 22. the transplanted liver suffered from what 
appeared to be a severe persistent ischaemic injury. Biopsy of 
the kidney on day 14 revealed an active interstitial and 
vascular rejection with arterial deposition of IgG and C3. 
Eventually both grafts were removed on day 54. and both 
showed evidence of rejection at that time. He received a 
second liver but died of septic gangrene of the abdominal wall 
35 days later. 
Patient 28 had received two liver transplants one year prior. 
hoth with a positive crossmatch and both of which failed due 
to rejection. He had cytomegalovirus infection and sepsis at 
the time of the combined transplant. Initially his kidney 
functioned well. but deteriorated possibly due to FK506, His 
third liver also functloned well initially. but he contlnued to 
have problems with sepsis and died 17 days post-transplant. 
Influence of PRA on patient and graft survival 
PRA levels were available for 35 palient~ prior to trans-
plantation. as shown in Table I, and the HLA defined private 
andlor public specificity of the preformed antibodies were 
identified where pOSSible as previously described. 14 Nineteen 
of 23 patlents (IB%) with PRA :slO% are still alive. and all 
hut one has a functioning kidney. whereas only live of 12 
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figure 2 Actuanal patient (left) and kidney (right) allograft survival of combined liver-kidney transplant recipients in correlation with 
pretransplanl donor specific lymphocytotoxic crossmatch results: (.), negative crossmatch, n = 32; (el, positive crossmatch, n = 6. 
patients (42%) with a high PRA (> 10% ) have survived and 
one has lost his kidney allograft. The majority of the high 
PRA patients who suffered from death and/or organ failure 
(5/8) also had a positive crossmatch. 
Of the 12 patients with a current PRA > 10%. HLA 
specilicitics could be determined in eight (Table 3). Three of 
1 he 12 received donor organs which carried the specific 
antigen. and all had positive crossmatches as expected. Two 
of the remalOing three positive crossmatch patients had very 
hi!1,h PRAs ( >90% ) which made defining the antibody speci-
ficitv impossible. and the third (patient II) had a defined 
specificity which was not present on the donor but also had a 
large degree of additional reactivity which could account for 
the positive crossmatch. 
Of the .,ix patients with a current PRA ;.> \0% but a 
Tlc!1,atlve crossmateh. four (patients lJ. 1 h. 35 and 38) had a 
dctined speelticity against an antigen whIch was not on the 
donor cells. and two (patients 13 and 15) had an undefined 
'peclticitv wtth a relative Iv low PRA. 
('he cltnieal course of the six high PRA patients with a 
posllive erossmatch has already heen outlined in Table 2. The 
dlOieal course of the remaining high PRA patients is shown in 
fabk 4. Only three of them tailed (patIents lJ. 15 and 16). 
Table 2 (·Iinlcal coursc of patients wllh posItive crossmatch 
Patlcnt POlllent survIval (hilan survIval <. 'ause ot" organ loss 
number (months) (months) 
Liver Kidnev Liver 
.j 
·7R .·7R ·7R 
() .j .j .j Death. no re)eClIOn 
·.jX ··.jX 0 
11 1).9 0.9 0.9 Death. no re)ectlon 
3 2 ,. Ischaemlc injUry 
2S 1).6 O.ll tl.5 Death. no rejection 
'Kidnev ncvcr iunctloned. was removed at liver retransplantatlon. 
CMV. cytomegalovirus. 
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Patient 9 is the second so-called 'canary kidney' described by 
Starzl et aJ. 13 The kidney never functioned and showed signs 
of humoral rejection. The patient also developed primary 
nonfunction of the liver and retransplantation was attempted 
on postoperative day three, but he succumbed to systemic 
sepsis. 
Patient 15 suffered from a portal vein stricture almost three 
years posttransplant. He underwent a second liver transplant. 
but died 15 months later of sepsis. Patient 16 developed 
hepatitis B posttransplant and died of liver failure and sepsis 
without retransplantation. There was no evidence of rejection 
in either the kidney or liver. 
Patient 24 is also shown in Table 5. He had 0% PRA at the 
time of transplant. but had a strong HLA-A2 specific anti-
body in an historical serum sample. The A2 antigen was 
present in the donor. and the historical crossmatch was 
positive. The liver functioned poorly and the patient was 
diagnosed with hepatic artery thrombosis two months post-
transplantation. He died of liver failure and sepsis WIthout 
retransplantation. 
Five patients with PRA :s 10 and a negative crossmatch died 
posttransplant and one suffered from failure of his renal 
allograft (Table 5). Patient 12 suffered from a hepatic artery 
Cause ot patient loss 
Kidney 
Still alive 
Dcath. no re)ecllon P1It'llmo(·\'.WS carmI; 
Humoral and cellular re)CCllOn Still alive 
Death. no reJecllon Pre-exlsllng sepsis. CMV 
Humoral and cellular rejection Retransplantallon. wound sepsIs 
Drug toxicitv Pre-existing sepsIs. CMV 
h 
Table] Histocompatibility profile and antibody specificity of high PRA recipients 
HLA recipient Current Current Antibody HLAdonor Pat.ient 
PRA specificity" 
number crossmatch A B DR A B DR 
2.- 51.57 2.- Positive 94 Undefined 1. 8.35 3.5 4 8.51 3.5 25.32 18.44 4.6 Positive 20 Weak P02 1I~ 6 1.2 8.57 3. 7 
7 2.24 7.27 8.- Positive 91 Undefined 
9 1.2 35.- 4.5 Negative 20 AlO 1. -
7.- 7.-
II 24.- 44.- 5.6 Positive 64 P02+? 1.24 
35.57 6. 7 
13 3.- 7.35 2.- Negative 26 Undefined 2.-
7.51 2.5 
15 2.29 7.44 6. 7 Negative 29 Undefined 2.28 
14.62 5.6 
16 26,31 14.35 1.- Negative 14 B17 2,11 7.35 6.8 
22 2,28 7.62 2.4 Positive 98 PSI + P71 3.- 7,60 2,6 
24 32,- 18.53 5, 7 Negative 0 A2b 2. 29 7.49 1.6 
28 24,33 58.60 NO Positive 84 B12, B7. B22 2. 29 44.50 4. 7 
35 11,32 35.44 7,- Negative 13 WeakA2 26.36 53,58 4. 7 
38 30,31 38.51 7,- Negative 28 A3 2,31 60.- 4.13 
• Private and public specificities were determined by panel cell analysis using a X" tailed analysis as previously described.13 Public specificities are 
defined as follows: P02 = A2, A28; PSI = A9. A32. Bw4; P71 = A!' A3. A9. AID. All. 
hSpecificity of historic serum. which was crossmatch positive. Current serum was crossmatch negative. 
NO. not determined. 
Underlined antigens indicate those included in the defined antibody specificities. 
Table 4 Clinical course of negative crossmatch patients with panel reactive antibodies (PRA) > 10% 
Patient 
number 
Patient survival Organ survival Cause of organ loss Cause of patient loss 
(months) (months) 
Liver Kidney Liver Kidnev 
l) 
lJ 
15 
16 
.\5 
.Iii 
0.2 0.1 0 Primary nonfunctlOn Humoral rejcction Retransplantation. st!psis 
>46 >46 >46 Still alive 
50 35 50 Anery thrombosis Dt!ath. no rejection St!psis 
5 5 Hepatitis B 
>17 >17 >17 
>11 >11 >11 
thrombosis and eventually succumbed to sepsis after a third 
liver was transplanted. The kidney showed no signs of rejec-
lion at autopsy. 
Patient 14 resumed dialysis aiter failure of his kidney 35 
months post-transplantation. and a biopsy that at that time 
showed eVidence of chronic rejection. His liver continues to 
functIOn well, as docs a second kidney transplant received ten 
months alter failure of the tirst. Patient 24 had a positive 
histOrical erossmatch and is described above. Patient 27 died 
from recurrence of his original disease (oxalosis). Patient 29 
Death. no rejection Retransplantation. pneumonia 
Still alive 
Still alive 
lost his liver due to severe ischaemic injury and sepsis and 
died of sepsis three days after retransplantatlon. 
The tinal patient shown in Table 5 (patient I) had a 
negative crossmatch hut PRA was not determined. She died 
of sepsis and pancreatitis on postoperative day 16. with no 
evidence of rejection in either transplanted organ. 
Effect of OTT treatment of the sera 
Crossmatches on 19 patients (patients 20-38) were also 
performed using sera treated with dithiothreitol (DTI), 
Tlible 5 Causes of patient and grail loss 10 pallems wilh low PRA and/or ne!1,ative crossmatch 
1';1I1<:nt Donor 
Ilumher c:rossmatch 0;, PRA 
:'>Icgatlvc :'>ID 
12 'iegallve 2 
f~ '«:gallvc II 
O~ "egatlve il 
I~ 
:'-Iegallvc , -, 
-
29 :'-Iegallve II 
Pallcm surVival 
Imonlhs) 
II.S 
1 
K-·~R 
2 
S 
11.6 
Organ surVival 
(months) 
Liver Kidnev 
tl.5 II.) 
0.3 I 
I~F ,'5 
2 2 
S II 
11.5 11.6 
1':lllcnl l~ had pnor anllbody agamst A2 anlll!en camed hv donor. 
-..; (), nOI determmed. 
;·rlllI.\p/UIII /mnlll1l%r{Y 19'14: 2: 61417 
( 'ausc 01 organ loss ( 'ause 01 pallent loss 
Livcr Kidnev 
Dcath, no relecllon Death. no relccllon Pancrealllls, sepsis 
Artery thrombOSIS Death, no rejection Rctransplanlallon, sepsIs 
Cellular rClecllon Still alive 
Arterv Ihrombosls Death. no rClectlon Liver lallure. sepsIs 
Oxalosis Oxalosis Liver failure, sepsis 
Infection, ischaemia Death, no reJeClion SepsIs 
which removes nonspecific IgM antibodies. 15 Such treatment 
did not change the crossmatch results. even of the two 
patients with a positive crossmatch (patients 22 and 28). Drr 
treatment of serum resulted in slight decreases it! PRA in 
some of the high PRA patients. but it did not affect the 
antibody specificities or the overall results. 
Influence of other factors 
HLA-A, -S and -DR typing was available on 30 donor and 
recipient pairs. Overall. the degree of matching was poor. as 
would be expected for random allocation of donor organs. 
The average number of mismatches was 4.4 (out of a possible 
six). There was no difference between the mismatches in the 
positive or negative crossmatch groups (4.6 vs 4.3). 
The ability of the liver allograft to influence the antibody 
status of the recipient was also examined. All six of the 
patients who had a strongly positive crossmatch before the 
liver transplant had the crossmatch repeated with sera taken 
after liver transplantation but before the kidney was put in. 
Three patients (patients 4. 6 and 28) went from a strongly 
positive crossmatch to a negative crossmatch. In all three of 
these patients. the liver allografts were functioning during the 
immediate posttransplant period and there was no evidence 
of hyperacute rejection in any of the kidneys. In patient 7. the 
crossmatch remained strongly positive after transplantation 
and the kidney never functioned. In pattent 22. the cross-
match went from strong positive to weakly positive. A kidney 
biopsy on day 14 showed evidence of humoral rejection. 
Interestingly. the liver allografts in both these patients func-
tioned poorly from the start. The sixth patient (patient 11) 
had last received OKT3 four days prior to the combined 
transplant. The crossmatch went from strong to weakly 
positive. but he had good liver and kidney function in the 
immediate posttransplant period. 
Previous organ transplantation appeared to have a delete-
rious effect on outcome. Of the 13 patients who had pre-
viously undergone organ transplantation prior to 
simultaneous liver-kidney transplantation. seven are still 
alive (54%). compared to 19 out of 25 (76% ) of the patients 
who had no prior transplants. In addition. all six patients who 
required retransplantation of the liver after the combined 
transplant died. 
Discussion 
As the indications for transplantation of solid organs in-
creases. the need for multiple organ transplantation will rise. 
There have been a number of published reports on the 
success of such transplants.J4 The question of whether lym-
phocytotoxic antibodies are a contraindication to such trans-
plants has been raised. We have attempted to correlate 
patient and graft survival with the immunological status of the 
recipients. 
I n general. renal transplantation across a positive cross-
match results in hyperacute rejection. 1o hut the liver is 
thought to be relative Iv resIstant to antibodv-mediated in-
jury.1,·IH In fact. we ha've previously reported two cases in 
which a liver transplant across a positive lymphocytotoxic 
crossmatch protected a subsequent kidney transplant from 
hyperacute rejection.O.7 but other studies have demonstrated 
that the liver does not always playa protective role.I.I.I" In 
addition. recent studies from this centre indicates that a 
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posltive crossmatch may have an adverse effect on liver 
allograft survival.J.4 Demetris et ai.2O reported that a series of 
livers transplanted across a positive crossmatch did not show 
'hyperacute' rejection. but numerous pathological changes 
including findings similar to preservation injury. cellular 
rejection, arterial vasospasm and focal large bile duct necrosis 
were seen. 
The data presented here indicate that combined liver-
kidney transplantation results in patient survival comparable 
to that seen in patients receiving liver allografts alone. and 
thus kidney failure should not be a contraindication for liver 
transplantation. Even in the presence of specific HLA anti-
bodies. a liver transplant can protect a subsequent kidney 
transplant from hyperacute rejection as previously descri-
bed6•7 but such protection is not absolute. 
The effect of a positive crossmatch on long-term graft 
survival is less clear. Whereas 78% of the patients with a 
negative crossmatch are alive with both organs functioning. 
only two of six patients with a positive crossmatch are alive 
and one of these survivors lost his kidney graft. Two of the 
patients showed signs of kidney rejection and all three who 
died had sepsis. There is a statistically significant difference 
between the groups in spite of the low numbers of patients. 
High PRA levels may impact patient and graft survival in 
liver transplant patients by influencing other parameters such 
as blood usageK~1 In this study. an adverse relation of patient 
survival with PRA exists. although most of the high PRA 
patients who failed also had a positive crossmatch. 
It is interesting to speculate on what. if any. differences 
would be seen in the results if a more sensitive crossmatch 
technique such as antihuman globulin enhancement or flow 
cytometry had been used. It is possible that some of the high 
PRA patients with negative crossmatches may have had 
donor specific antibodies below the level of detection with the 
Amos modified crossmatch. This is especially true of patient 
9. who showed evidence of antibody-mediated rejection in the 
kidney despite a negative crossmatch. U 
There are numerous clinical parameters which can affect 
survival after liver and/or kidney transplantation. including 
status of the recipient prior to the transplant (UNOS score). 
wndition of the donor organs. cold ischaemia times. donor 
and recipient age. and original disease of the recipient. None 
of these factors have been addressed in this study but will be 
analysed in a subsequent study to he published. The effect of 
prior transplants. including an analysis of their type and 
timing. is also a critical issue that will be addressed in more 
detail. 
It has been demonstrated in animal models that trans-
plantation 01 liver allo!!'ralts protects other organs suhse-
4uently transplanted into sensitized recipientsK~~·~g with a 
decline of donor specific antibodies following liver trans-
plantation. c., G u!!.enheim e( a/. 24 showed that prolonged sur-
vival and decrease in antibodies was accompamed hy 
deposition of immunoglobulin and C3 on hepatic nonpar-
enchymal cells. supporting the hypotheSIS that the protective 
effect of liver transplantation and its resistance to hyperacute 
rejection might he due to absorption of lymphocytotoxic 
alloantibodies on nonparenchymal hepatic cells. Furuya e( 
al. 2' noted a direct correlation hetween titre of Iymphocvto-
toxic antibodies and graft survival. and IgG antibodies were 
shown to be more destructive than IgM. The variability we 
have seen in the abilitv of the liver to protect a subsequent 
kidney from immune attack is likely related to titre and class 
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of antibody present. However. antibody titres were not 
routinely determined for these patients. and only two of the 
positive crossmatches were performed using DlT treated 
serum. Further studies are also needed to determine why only 
half of the positive crossmatches became negative after the 
liver was transplanted. Possible explanations include differ-
ences in antibody titre or differences in function of the 
transplanted liver. 
The liver is a unique organ in the study of transplantation. 
Much of the lore of the immunobiology of liver transplanta-
tion can be translated into liver specific phenomena. The 
application of some of these findings into clinical settings may 
aid in expanding indications for transplantation. The experi-
ence of combined liver and kidney transplantation compares 
favourably with liver transplantation alone. Also. like liver 
transplantation, prior organ transplantation andlor the need 
for subsequent retransplantation has a deleterious effect on 
patient survival. Preformed lymphocytotoxic antibodies are 
not an absolute contraindication to combined liver-kidney 
transplantation. but do appear to have a deleterious effect on 
long-term graft survival. Further studies with larger numbers 
and more correlation with clinical parameters are needed 
before a definite conclusion can be reached. It is possible that 
enhanced immunosuppression or the use of prophylactic 
treatment with prostaglandin may improve graft survival as it 
has in liver transplantation.:b 
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